Understand the source comparison
SS-LUP-332 Before and After Real Results: Comparison
SS-LUP-332 REV-ERB agonist. Increases mitochondrial fat oxidation, suppresses lipogenesis 12–18% in 28 days (rodent data) Complete preservation. No lean mass loss observed None as of 2026. Preclinical only Most selective fat-loss profile in preclinical data, b
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- SS-LUP-332
- REV-ERB agonist. Increases mitochondrial fat oxidation, suppresses lipogenesis
- 12–18% in 28 days (rodent data)
- Complete preservation. No lean mass loss observed
- None as of 2026. Preclinical only
- Most selective fat-loss profile in preclinical data, but zero human validation limits real-world applicability
- Semaglutide (GLP-1)
- GLP-1 receptor agonist. Slows gastric emptying, reduces appetite signaling
- 10–15% over 68 weeks (STEP-1 trial)
- Partial. 20–40% of weight lost is lean mass
- Extensive Phase 3 data in humans
- FDA-approved with established dosing, but muscle loss is a documented limitation
- Clenbuterol
- Beta-2 adrenergic agonist. Thermogenic, increases lipolysis
- 5–8% over 8 weeks (off-label use)
- Variable. Muscle sparing depends on protein intake and training
- Limited human data. Veterinary compound
- Significant cardiac side effects, tachyphylaxis develops within 2 weeks
- DNP (2,4-dinitrophenol)
- Mitochondrial uncoupler. Forces ATP production through heat instead of storage
- 8–12% in 2–3 weeks (anecdotal)
- Poor. Catabolic at effective doses
- Banned for human use. No controlled trials
- Extremely dangerous. Narrow therapeutic window, fatal overdoses documented
- SS-LUP-332 stands out for muscle preservation, but the complete absence of human dosing, safety, or efficacy data means all comparisons are theoretical. The compounds with human evidence (semaglutide, clenbuterol) have known side effect profiles and dosing parameters; SS-LUP-332 does not.